US Stock MarketDetailed Quotes

Merus(Delisted) (MRUS)

Watchlist
  • 0.000
  • 0.0000.00%
Close Jan 23 09:30 ET
0Market Cap0.00P/E (TTM)

About Merus(Delisted) Company

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Company Profile

SymbolMRUS
Company NameMerus(Delisted)
Issue Price10.00
CEODr. Jan G. J. van de Winkel, PhD
MarketNASDAQ
Employees260
Fiscal Year Ends12-31

Company Executives

  • Name
  • Position
  • Salary
  • Dr. Jan G. J. van de Winkel, PhD
  • Director and Chief Executive Officer
  • --
  • Harry Shuman
  • Chief Accounting Officer
  • --
  • Gregory D. Perry
  • Chief Financial Officer
  • 3.26M
  • Dr. Fabian Zohren, M.D.,PhD
  • Chief Medical Officer
  • 6.94M
  • Greg Mueller
  • Director
  • --
  • Anthony Pagano
  • Director
  • --
  • Dr. Martine J. van Vugt, PhD
  • Director
  • --
Market Insights
Nancy Pelosi Portfolio
China Concept Stocks
View More
The Fed Delivers Third Consecutive Rate Cut as Expected! How to Position for Year-End U.S. Equity Ma
On December 19, the Bank of Japan raised interest rates by 25 basis points as expected, in line with market forecasts. On the evening of Dec Show More